Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $1.90 Million |
|---|---|
| Enterprise Value | $1.88 Million |
| Earnings per Share | $-0.12 |
| Beta | 0 |
| Outstanding Shares | 16,072,267 |
| P/E Ratio | -1.11 |
|---|---|
| PEG | -0.3 |
| Price to Sales | - |
| Price to Book Ratio | -0.13 |
| Enterprise Value to Revenue | 19.12 |
| Enterprise Value to EBIT | -0.58 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
AccuStem Sciences, Inc. operates as a life science firm committed to improving the outlook for individuals battling cancer. Its primary innovation is the StemPrintER technology, an advanced multi-gene prognostic assay designed to predict...